阿得贝利单抗一线治疗广泛期小细胞肺癌的药物经济学评价  

Pharmacoeconomic Evaluation of Adebrelimab in the First-Line Treatment of Patients with Extensive Small Cell Lung Cancer

作　　者：胡钊 刘永军[1] HU Zhao;LIU Yong-Jun(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药物经济学》2025年第3期9-16,共8页China Journal of Pharmaceutical Economics

摘　　要：目的对阿得贝利单抗联合标准化疗与单用化疗一线治疗广泛期小细胞肺癌(ES-SCLC)的经济性进行评价。方法通过构建三状态分区生存模型进行研究,以我国医疗卫生体系为研究角度,研究对象为ES-SCLC患者,模型周期为21 d,研究时限为患者终生。运用成本-效用分析方法对两种治疗方案进行药物经济学分析,并用敏感性分析验证结果的稳健性。结果对于ES-SCLC患者,阿得贝利单抗联合化疗方案相较于一线化疗方案的增量成本-效用比(ICUR)值为824842.22元/QALY,大于我国2023年3倍人均GDP,可能不具有经济性。敏感性分析与基础分析结果一致,显示基础分析结果较为稳健。情境分析结果显示,当开展慈善赠药方案或实行医保价格后,阿得贝利单抗联合化疗方案具有成本-效益。结论在我国2023年3倍人均GDP阈值下,对于ES-SCLC患者,阿得贝利单抗联合化疗方案相较一线化疗方案可能不具有经济性。Objective To conduct an evaluation of the economics of combination of Adebrelimab and standard chemotherapy and chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer(ES-SCLC).Methods The study was carried out by constructing a three-state partition survival model.Taking our country's health care system as the research perspective,the research objects were patients with extensive-stage small cell lung cancer,and the model period was 21 days.The pharmacoeconomic evaluation of the two treatment regimens was conducted by cost-utility analysis,and the robustness of the results was verified by sensitivity analysis.Results For patients with ES-SCLC,the ICUR value of Adebrelimab combined with chemotherapy compared with first-line chemotherapy was 824842.22 yuan/QALY,which was more than three times the GDP per capita in 2023,which may not be economical.The results of sensitivity analysis were consistent with the basic analysis results,showing that the basic analysis results were relatively robust.The results of the contextual analysis showed that the adebenosumab combination chemotherapy regimen was cost-effective when a charitable gift program was conducted or when adebenosumab entered Medicare reimbursement.Conclusion Under the threshold of 3 times the GDP per capita in our country in 2023,for patients with ES-SCLC,Adebrelimab combined with chemotherapy may not be economical compared with first-line chemotherapy.

关 键 词：阿得贝利单抗 程序性死亡受体配体1 广泛期小细胞肺癌 分区生存模型 药物经济学评价 

分 类 号：R734.2[医药卫生—肿瘤] R956[医药卫生—临床医学]